603079 圣达生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.8284.3692.339-4.1872.378
总资产报酬率 ROA (%)0.6003.1201.679-3.2041.841
投入资产回报率 ROIC (%)0.6513.4331.846-3.5562.066

边际利润分析
销售毛利率 (%)27.60226.15321.26516.01017.729
营业利润率 (%)9.8189.4985.628-6.2794.898
息税前利润/营业总收入 (%)10.8768.9104.753-7.6631.984
净利润/营业总收入 (%)8.0938.2014.503-7.4514.124

收益指标分析
经营活动净收益/利润总额(%)93.082100.300106.6503.55882.778
价值变动净收益/利润总额(%)4.8732.6391.476-0.89728.456
营业外收支净额/利润总额(%)0.028-0.1085.132-0.8131.027

偿债能力分析
流动比率 (X)4.6874.0962.8192.3532.641
速动比率 (X)3.6423.3272.0341.5791.653
资产负债率 (%)25.63126.55228.08126.12818.836
带息债务/全部投入资本 (%)20.49020.21420.55819.8268.135
股东权益/带息债务 (%)383.060389.961380.705401.2801,115.623
股东权益/负债合计 (%)284.383271.443251.494279.317425.938
利息保障倍数 (X)10.309-15.433-4.0315.341-0.669

营运能力分析
应收账款周转天数 (天)67.01361.69455.16261.62864.096
存货周转天数 (天)134.556111.775117.711153.364152.423